A 12-foot great white shark, tracked from Nova Scotia, has been detected in the Mississippi Sound, marking an unusual westward migration into the Gulf and offering clues about the region's marine health.
Shares of Perspective Therapeutics (CATX) have rallied sharply following encouraging interim results from its lead cancer therapy trial and a strategic business update. While the data fuels optimism, a deep dive into the numbers reveals a stark disconnect between its current market price and analyst targets, highlighting both opportunity and significant risk.
The 179-year-old tobacco giant Philip Morris International is closing its Richmond, Virginia office, eliminating 135 positions, as it aggressively restructures around its smoke-free product portfolio, led by the ZYN nicotine pouch brand.
Nvidia is set to make a landmark investment in OpenAI's latest funding round, CEO Jensen Huang confirmed, signaling a deepening alliance between the AI hardware giant and the leading AI research lab. However, reports of internal skepticism at Nvidia introduce uncertainty into the final terms and timing of the deal.
Glaukos Corporation's iDose TR glaucoma therapy receives a key FDA labeling update, permitting repeat administration. While the news bolsters the company's growth narrative, analysts are divided on whether its current stock price already reflects future potential amid rich valuation metrics.
Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
The FDA's approval of a repeat treatment protocol for Glaukos's iDose TR implant transforms it from a one-time procedure into a potential chronic therapy platform, reshaping its commercial narrative and investor calculus in the competitive glaucoma market.
BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
Danaher Corporation announces a strategic investment in Automata, aiming to integrate AI-ready automation systems with its extensive portfolio of instruments and reagents. The move signals a push to deliver comprehensive, data-driven lab solutions as the life sciences sector increasingly prioritizes efficiency and scalability.
The healthcare behemoth's robust 2025 results and 2026 guidance signal a landmark year ahead, as it navigates patent expirations and pricing pressures while maintaining its coveted dividend king status.
Barclays' stock has delivered a stellar 68% total return to shareholders over the past year, fueled by strong revenue and profit figures. As the share price approaches analyst targets, investors are weighing whether the current valuation still offers value or if the easy gains have been made.
Despite a robust drug pipeline and steady long-term gains, AstraZeneca's recent share price stagnation has investors questioning its true worth. A deep dive into valuation models suggests the pharmaceutical giant may be trading at a significant discount to its intrinsic value, even as its P/E ratio appears elevated compared to peers.
Facing softer demand and tariff volatility, Minerals Technologies (MTX) reported steady 2025 sales of $2.1B but saw margins contract. Leadership emphasized cost discipline and safety while detailing a series of expansion projects poised to drive a meaningful rebound in the coming year.
Novo Nordisk's newly launched oral GLP-1 drug, amycretin, has seen explosive initial demand in the U.S., potentially setting the stage for a significant financial turnaround and stock rally after a challenging previous year.
Merck & Co. shifts its cancer drug development playbook, opting for targeted collaborations with Guardant Health and Eikon Therapeutics after walking away from a major acquisition. Analysts debate whether the stock's current price fully reflects its long-term pipeline potential.
Dover Corporation (DOV), the diversified industrial manufacturer, continues to attract heavy institutional investment, driving a remarkable long-term share price appreciation. Strong quarterly earnings and bullish guidance underscore the fundamental strength behind the sustained Big Money inflows.
New industry data reveals fashion's climate progress has stalled, with coal reliance remaining high and renewable energy adoption minimal. As the easy wins fade, experts call for targeted investment and collective action to tackle the sector's most polluting facilities.
The FDA's Priority Review for Vyvgart's label expansion in myasthenia gravis accelerates Argenx's growth strategy, while investors weigh the company's broader pipeline against its current valuation.
